3 results
Primary: efficacy of GSK1605786 at week 12 following twice daily administration at 500 mg in patients with active ulcerative colitis. Secondary: safety and tolerability, time course of the efficacy of GSK1605786 continued for up to 16 weeks, anti-…
The purpose of this study is to analyse the effect on pain reduction of butylscopolamine in a continuous intravenous infusion compared to a placebo in patients with renal colics not responding to oral NSAIDs.
To evaluate the feasibility of MCRRF therapy in women with persisting perineal pain after episiotomy. Collection of pilot data is essential in the preparation of a larger randomized-controlled trial that investigates the efficacy of MCRRF therapy.